BridgeBio Pharma (BBIO)
(Delayed Data from NSDQ)
$24.88 USD
+0.55 (2.26%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $24.91 +0.03 (0.12%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
BBIO 24.88 +0.55(2.26%)
Will BBIO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BBIO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BBIO
Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know
Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges
BBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bayer (BAYRY) Acquires BridgeBio's Cardiovascular Drug
BridgeBio Pharma (BBIO) Reports Q4 Loss, Lags Revenue Estimates
Analysts Estimate BridgeBio Pharma (BBIO) to Report a Decline in Earnings: What to Look Out for
Other News for BBIO
June 7th Options Now Available For BridgeBio Pharma (BBIO)
First Week of January 2026 Options Trading For BridgeBio Pharma (BBIO)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio reports inducement grants under Nasdaq listing rule
Buy Rating Affirmed for BridgeBio Pharma on Acoramidis’ Positive ATTR-CM Trial Outcomes